Welcome
PH1 is a life-limiting disease of oxalate overproduction that can affect adults and children and lead to recurrent urolithiasis, nephrocalcinosis and progressive renal decline, ultimately ending in end-stage kidney disease (ESKD) and death1.
Both symptoms and management approaches place a significant burden on patients and families, including hyperhydration, intensive dialysis and even liver/kidney transplantation1,2.
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Developed by EPG Health for Medthority.com, with all content provided by Alnylam Pharmaceuticals. Learning Zone sponsored and funded by Alnylam Pharmaceuticals. Please note that this material is intended for healthcare professionals only.
Date of preparation: February 2021 │ OXL-CEMEA-00006
© Copyright 2021